Translating an allogeneic adipose-derived MSC platform from an early clinical concept to GMP manufacturing

In the arena of advanced therapies, a process that cannot be meticulously measured cannot be controlled. The true test of clinical translation is not merely expanding cells, but defining, locking, and proving their identity at every single step of their industrial journey. To transform the initial biological protocol into a disciplined, commercially viable manufacturing platform, Cell-Easy approached Process and Analytical Development not as sequential tasks, but as an integrated, co-dependent ecosystem.

By running deep analytical characterization in parallel with downstream engineering, our teams successfully built a high-resolution “analytical lens” capable of detecting and neutralizing manufacturing drift before it could ever impact the final product.

The Co-Development Synergy: PD, Ops and Quality from Day One

The transition from a laboratory bench protocol to a robust clinical process is where many promising ATMPs stall due to the “tech transfer gap.” To eliminate this risk, Cell-Easy’s Process Development (PD) team took the lead on the CellReady program, functioning in continuous, daily consultation with the Production (Ops), Quality Control (QC), and Quality Assurance (QA) departments.

By embedding GMP realities into early-stage R&D, every process iteration was co-designed to be inherently GMP-compliant. No manufacturing parameter was validated in a vacuum.

The cross-functional teams meticulously integrated the harsh operational constraints of a Grade A/B cleanroom environment from the very outset, variables that early-stage preclinical developers rarely have to consider, but which can jeopardize an entire program if discovered too late:

• the extended timelines induced by rigorous operator gowning protocols (GMP _ Annex 1 compliance) and strict line clearance procedures.
• the biological holding windows, successfully engineering the process so that cellular viability remains uncompromised during mandatory operator transit times, gowning transitions, and strict multi-step material transfer airlocks.
• the administrative burden and physical duration of real-time Batch Record documentation, executed concurrently alongside manufacturing tasks.
• the fixed footprint and specific technical specifications of the validated instrumentation already qualified within the GMP suites, including the precise scheduling of periodic metrology and recalibration windows.

This anticipation ensured that the CMC and Regulatory package was built into the process DNA from Day One, drastically compressing the timeline to clinical entry.

Raw Material qualification

To build a reproducible and scalable manufacturing process, robust analytics must come first. Analytical methods act as the high-resolution lens required to evaluate how any process modification impacts the final Critical Quality Attributes (CQAs) of the ad-MSCs. Cell-Easy established a levelled analytical implementation strategy:

Raw Material qualification

The transition from research to clinical manufacturing also required a systematic review of raw materials. Legacy R&D reagents, including bovine-derived serum and animal-origin dissociation enzymes, were evaluated and progressively replaced with chemically defined or GMP-grade alternatives where appropriate.

The objective was to establish a more consistent raw-material baseline and reduce potential sources of variability and regulatory concern.

Minimizing the QC Sampling Burden to Maximize Commercial Yield

Cell therapy manufacturing presents a particular challenge because QC testing can consume a significant fraction of the manufactured product. The CellReady analytical strategy therefore considered the volume required for destructive and non-destructive testing when defining the manufacturing process. Compendial assays for sterility, mycoplasma, and endotoxins can consume an unsustainable percentage of a clinical batch, significantly reducing the final deliverable vial count.

To counteract this, our analytical alignment targeted the optimization of the QC sampling burden. This rigorous management guarantees that the highest possible ratio of manufactured cells is preserved for patient doses rather than being consumed by destructive analytical testing.

Critical Downstream Points of Vigilance

Several downstream operations were identified as requiring specific development and control:

• Downstream Bulk & Thermal Management: Large-volume cell suspensions can be sensitive to temperature during harvesting and downstream processing. The CellReady process therefore incorporated controlled temperature conditions during critical handling steps, including low-temperature management in the 2–8°C range where appropriate. The objective was to limit metabolic and physical stress before final formulation.

• Hydrodynamic Shear Stress Mitigation: Cell concentration and washing steps required attention to flow conditions and pumping. Flow rates and low-shear pumping conditions were evaluated to minimize mechanical stress and unwanted cell loss during downstream processing.

• Dose Homogeneity & Sedimentation Control: For automated fill-and-finish operations, cell sedimentation can affect dose uniformity if suspension conditions are not adequately controlled. Agitation and handling parameters were therefore assessed to maintain suspension homogeneity throughout the filling operation. The objective was to maintain consistent cell concentration from the beginning to the end of the filling sequence.

• The Cryopreservation Race: The Fill & Finish and cryopreservation parameters were extensively tested using a Quality by Design approach to define an optimal process.

• Automated Freezing Profiles & Post-Thaw Fitness: Controlled-rate freezing (CRF) profiles were characterized using multi-point temperature probes to ensure consistent freezing conditions. This helped minimize cryo-concentration gradients and achieve reproducible post-thaw cell recovery, with high viability.

Long-Term Cryogenic Stability & Structural Optimization

Long-term stability was incorporated into the development strategy from an early stage. The freezing and thawing conditions were evaluated under the intended cryogenic storage conditions, with stability studies designed to assess product quality over extended storage. The development program included storage at approximately −170°C and assessment of stability beyond five years under the defined conditions.

Supporting the First-in-Human program

To support the AlloFIST clinical trial application, Cell-Easy aligned its non-clinical safety strategy with the strictest regulatory standards. In accordance with French regulations, we conducted all pivotal in vivo toxicology and safety studies in compliance with Good Laboratory Practice (GLP) principles, as cross-referenced in Annex IV of the French Public Health Code (Annexe IV au Code de la santé publique – Article R. 5121-220). This provision requires sponsors to conduct any non-clinical safety study intended to evaluate the safety of a medicinal product in compliance with GLP standards, ensuring data integrity and traceability for competent authorities.

This absolute compliance was instrumental in securing our rapid, single-round regulatory clearance.

Key Pillars of the In-Vivo Safety Package

Our IMPD non-clinical safety evaluation focused on demonstrating a clean profile across pivotal biological benchmarks:

• Acute and Sub-Chronic Toxicity: Evaluating the systemic tolerance of the target clinical dose. The study design demonstrated the complete absence of any adverse systemic reactions, organ toxicity, or behavioral changes following administration.

• Local Tolerance & Systemic “Worst-Case” Safety: Given that the clinical indication (Crohn’s anal fistulas) requires precise localized delivery, verifying tissue tolerance and acute toxicity was paramount. To strictly de-risk the asset, Cell-Easy deliberately adopted a regulatory “Worst-Case Scenario” model for its in-vivo studies. Instead of limiting the evaluation to localized administration, the team conducted the pivotal safety assessment using systemic intravenous (IV) injection. This forced immediate, full-dose systemic exposure to challenge the platform against acute systemic toxicity, emboli risks, or organ stress. The pre-clinical data confirmed excellent tolerance with zero adverse systemic or local inflammatory responses, establishing an uncompromised safety profile even under maximum physiological stress.

• Biodistribution and Clearance: Tracking the fate of the ad-MSCs in vivo to ensure the cells localized at the target site to exert their therapeutic effects, or are cleared safely by the organism without unexpected, long-term accumulation in non-target major organs (such as the lungs, liver, or spleen).

• Tumorigenicity and Genomic Stability: Addressing the fundamental regulatory hurdle for any cell therapy platform expanding through multiple population doublings. The in-vivo data successfully demonstrated the absence of ectopic tissue formation or tumorigenic potential, validating the genomic stability of the cell porduct.

• Vehicle & Excipient Safety Profile: To fully de-risk the clinical use of the cryopreservation vehicle, our pivotal in-vivo murine toxicology screening evaluated the final formulation vehicle alone (Human Serum Albumin combined with DMSO). Showcasing zero local or systemic toxicity, this exact vehicle configuration was so robustly validated that it serves as the official, regulatory-approved placebo arm in our parallel clinical trial evaluating CellReady.

By generating this robust in-vivo safety dataset using the exact manufacturing blueprint intended for clinical supply, we removed any ambiguity regarding the safety of the platform. This clean toxicology package provided the definitive reassurance required by the regulators to authorize the AlloFIST trial with peace of mind.